Business Development contact for Partnering Inquiries
Dennis McNamara, Head of Business Development, leads our business development efforts and can be contacted at firstname.lastname@example.org.
Partnering: Our strategy
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers and viruses.
We have three core technologies, all of which are based on discoveries made by Dr. Waldemar Priebe and his team at The University of Texas MD Anderson Cancer Center. Our clinical stage drugs are Annamycin, a Next Generation Anthracycline targeting relapsed or refractory acute myeloid leukemia (AML) and lung metastases, WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML and WP1220, a close analog to WP1066, targeting cutaneous t-cell lymphoma (CTCL). We are also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors.
Moleculin plans to maximize its pipeline potential via a balance of internally driven initiatives and external collaborations and/or partnerships to explore existing and new indications, access additional geographies, and apply complementary technology to enable or enhance product attributes where appropriate. We currently collaborate with over ten entities – both institutional and commercial.
We’re actively looking for collaborations and partnerships where we can achieve goals together.
Our areas of interest
Moleculin seeks partnerships with a primary focus on:
- Partners that are interested in larger patient population indications in oncology and infectious disease utilizing one of our three core technologies
- Co-development partners in smaller patient populations with rare diseases
- Territory or Region-specific partnerships
- Transformative merger and acquisition opportunities
If you’d like to get in touch, please email email@example.com with your contact details and areas of interest.